New York, NY － Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, announced today that it has received a payment from Sanofi for reaching a major milestone in its multi-year, multi-target drug discovery collaboration. The project in which the milestone was achieved is one of several programs that Schrödinger is currently working on with Sanofi.

Under the terms of the collaboration, announced in 2015, Schrodinger agreed to provide comprehensive computational drug design support to Sanofi, from target analysis and validation to lead identification and lead optimization, for as many as ten drug discovery programs. Schrödinger is eligible to receive up to $120 million under the terms of the broad, multi-year relationship.